Intellia Therapeutics Inc (FRA:38I)
€ 21.68 -0.35 (-1.59%) Market Cap: 2.05 Bil Enterprise Value: 1.42 Bil PE Ratio: 0 PB Ratio: 2.16 GF Score: 56/100

Intellia Therapeutics Inc at Chardan Genetic Medicines Conference Transcript

Oct 03, 2022 / 12:30PM GMT
Release Date Price: €55.45 (-0.70%)
Geulah Livshits
Chardan - Analyst

All right, let's get started. So it's now my pleasure to introduce Dr. John Leonard, President and CEO of Intellia Therapeutics. The format for this session is a fireside chat that we can open to an audience Q&A at the end. John, thank you so much for joining us today.

Questions & Answers

Geulah Livshits
Chardan - Analyst

So Intellia has shared data recently from its two clinical stage in-vivo editing programs. Before we talk about those in more detail, can you give us a brief overview of where the company is now and go over the near-term catalysts and value drivers?

John Leonard
Intellia Therapeutics, Inc. - President & CEO

Sure. Good morning. Good to see you in person.

Yeah. So you'll remember we're a full-spectrum genome editing company. And so we think about the company in those terms, which means in-vivo side of the company, the ex-vivo side, as well as our platform.

And so on in-vivo side, as you mentioned, we have a couple of clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot